Designed for Precision.
Developed for Life.
At Adcendo, we are developing a new generation of antibody-drug conjugates (ADCs) engineered to address cancers with high unmet medical need.
Our programs are designed from the outset to translate scientific innovation into clinically differentiated medicines with meaningful outcomes for patients worldwide.
Latest News
Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates
ADCE-T02, a potential best-in-class Tissue Factor targeted antibody-drug conjugate (ADC), enters cohort expansion portion of the Tiffany-01 study in advanced solid tumors Two ADCE-T02 publications highlighting important preclinical results at the 2026 AACR Annual...
Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline
Oversubscribed financing led by Jeito Capital, including additional new investment from Vida Ventures, BPI France, and EIFO, with participation from all existing investors Proceeds to support the advancement of three first- and best-in-class ADC programs through...
Adcendo ApS Announces FDA Fast Track Designation Granted to ADCE-D01 for the Treatment of Soft Tissue Sarcoma
ADCE-D01 is a first-in-class antibody-drug conjugate targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypes Fast Track designation underscores the potential for ADCE-D01 to address the...